SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Determined man pushing several stones at once\
Job Trends
Show, don’t tell: doing free work during the interview process
Over one-third of BioSpace LinkedIn poll respondents have done free work while interviewing for jobs. A recruiting expert and career coach discuss why employers make work requests and how biopharma professionals should evaluate and respond to them.
April 30, 2026
 · 
6 min read
 · 
Angela Gabriel
Abstract vertical illustration of targeting cancer cell made of glowing neon particles. Blue geometric background depicting cancer cell screening and disease treatment medical concept. Digital vector illustration
Opinion
Tackling drug resistance must become biotech’s next frontier
We must treat drug resistance as a central scientific priority rather than an unavoidable complication.
April 30, 2026
 · 
5 min read
 · 
John Yu
AbbVie Leaps Into the Land of Oncolytics With New Turnstone Biologics Tie-Up
Earnings
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”
April 29, 2026
 · 
3 min read
 · 
Gabrielle Masson
Vector of a small businessman supported by unknown investor bridging the gap in his career path
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for some early-stage bets, CEO Chris Viehbacher said Wednesday.
April 29, 2026
 · 
3 min read
 · 
Annalee Armstrong
Stones in calm water with evening sun
Earnings
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including for LAG3 candidate fianlimab in metastatic melanoma.
April 29, 2026
 · 
3 min read
 · 
Heather McKenzie
Concept of success. Business men catch by hands stars in the sky. Flat design, vector illustration.
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
 · 
3 min read
 · 
Annalee Armstrong
Business handshake trendy halftone art collage banner template. Partnership concept, successful agreement, closing a deal, securing a contract. Modern retro cut out vector illustration
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
 · 
2 min read
 · 
Gabrielle Masson
Shanghai,China-August 24th 2025: AstraZeneca company office building
Earnings
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is in reach.
April 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.
Earnings
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the first quarter, emerging as the pharma’s top-selling product.
April 29, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS